Holen Sie sich die Stockscreener-App
8.23
3.27%
0.25
Schlusskurs vom Vortag:
$7.98
Offen:
$8.07
24-Stunden-Volumen:
1.03M
Relative Volume:
0.77
Marktkapitalisierung:
$645.27M
Einnahmen:
$311.71M
Nettoeinkommen (Verlust:
$163.05M
KGV:
4.1492
EPS:
1.9835
Netto-Cashflow:
$172.79M
1W Leistung:
+5.38%
1M Leistung:
+11.06%
6M Leistung:
-14.60%
1J Leistung:
-33.33%
1-Tages-Spanne:
$8.02
$8.295
1-Wochen-Bereich:
$7.64
$8.295
52-Wochen-Spanne:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.225 | 626.05M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
436.52 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.88 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.13 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.74 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.40 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
CorMedix eyes REZZAYO expansion as DefenCath reimbursement shift looms - MSN
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition - MSN
CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets - TradingView
CRMD Q1 earnings beat on DefenCath momentum, guidance raised - MSN
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms - Yahoo Finance
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix stock jumps as DefenCath fuels Q1 beat, 2026 outlook raised - MSN
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Cormedix Earnings Call Highlights Surging Growth, New Risks - TipRanks
CorMedix Q1 earnings call highlights - MSN
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD - MarketBeat
Needham Maintains CorMedix (CRMD) Buy Recommendation - MSN
Discipline and Rules-Based Execution in CRMD Response - Stock Traders Daily
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD) - Seeking Alpha
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD) - MarketBeat
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)? - Yahoo Finance
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results - simplywall.st
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance - Yahoo Finance
CorMedix Inc $CRMD Shares Bought by Vanguard Group Inc. - MarketBeat
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD) - The Globe and Mail
CorMedix (CRMD) Q1 earnings and revenues beat estimates - MSN
CorMedix Inc.Common Stock (NQ: CRMD - The Chronicle-Journal
symbol__ Stock Quote Price and Forecast - CNN
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - The Globe and Mail
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership - Stock Titan
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences - marketscreener.com
CorMedix Inc. (NASDAQ:CRMD) Q1 2026 Earnings Call Transcript - Insider Monkey
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised - Sahm
Cormedix Earnings Call Highlights Growth, Raises Outlook - TipRanks
CorMedix Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 98% Upside - TradingView
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
CorMedix Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
CorMedix (NASDAQ:CRMD) Issues Earnings Results - MarketBeat
CorMedix (CRMD) Q1 2026 Earnings Transcript - AOL.com
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
CorMedix 1Q EPS 43c >CRMD - Moomoo
CORMEDIX INC. Reports Q1 2026 Financial Results and Business Update – SEC 8-K Filing Details - Minichart
Transcript : CorMedix Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Earnings call transcript: CorMedix Q1 2026 revenue beats, stock surges - Investing.com UK
CorMedix Q1 Earnings Call Highlights - MarketBeat
CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance - Yahoo Finance
CorMedix Releases Q1 2026 Financial Results - AlphaStreet
CRMD: Q1 revenue and profitability exceeded expectations, driving higher full-year guidance - TradingView
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):